Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO Leave a reply CEO of family company Angelini Industries will also lead the pharmaceutical company from today, bringing strong leadership experience and strategic vision ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) — Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, today announced the appointment of Sergio Marullo di Condojanni as Chief Executive Officer. He has served as CEO of Angelini Industries since 2020 and will maintain that role while assuming leadership of the pharmaceutical division to drive cohesive strategy implementation, leveraging extensive executive, governance, and financial expertise. Jacopo Andreose, who led Angelini Pharma until the end of 2025, will become a member of the Angelini Holding board and a senior advisor to the Angelini Pharma board. The appointment is part of Angelini Industries’ multi-year effort to strengthen its corporate governance and operating model, building on the Group’s century-long heritage of pharmaceutical excellence. The transition aims to further solidify pharmaceutical healthcare as a core pillar of its long-term growth strategy alongside industrial technology. Thea Paola Angelini, Chair of Angelini Holding and majority shareholder, stated: “Appointing Sergio as CEO will drive simplified decision-making for our pharmaceutical business — the heart of our Group. This strategic choice will enable us to be closer to market needs and, above all, to patients, by delivering greater efficiency, agility, faster decision-making, and flexibility.” Marullo di Condojanni’s dual role will enable him to directly spearhead strategy implementation within the healthcare division, seeking to maximize the value of Angelini Pharma in a high-growth sector. He will focus on further elevating the company’s leadership in Brain Health, with particular attention to rare neurological diseases, while continuing to build on its legacy in Consumer Healthcare. He will also prioritize expanding Angelini Pharma’s global reach, including
